4-(2-羟基乙基)苯甲醛 | 163164-47-4

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-羟基乙基)苯甲醛
• 中文别名: 4-羟乙基苯甲醛；苯甲醛,4-(2-羟乙基)-(9CI)；4-(2-羟乙基)苯甲醛
• 英文名称: 4-(2-hydroxyethyl)benzaldehyde
• 英文别名: 4-mono(2-hydroxyethyl)benzaldehyde
• CAS: 163164-47-4
• 化学式: C₉H₁₀O₂
• 分子量: 150.177
• InChiKey: VNVVFWYCFVNBMI-UHFFFAOYSA-N

物化性质

• 沸点：
  295℃
• 密度：
  1.142
• 闪点：
  124℃
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2912491000
• 储存条件：
  存储条件为2-8°C，并需保存在惰性气体环境中。

反应信息

• 作为反应物：
  描述：

  4-(2-羟基乙基)苯甲醛 在 对甲苯磺酸 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 17.0h， 生成 ethyl (E)-7-[4-[2-[4-(1,3-dioxan-2-yl)phenyl]ethoxy]phenyl]-7-pyridin-3-ylhept-6-enoate
  参考文献：
  名称：

  A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the Link of 1,3-Dioxane-Thromboxane Receptor Antagonists and -Thromboxane Synthase Inhibitors

  摘要：

  A new class of dual-acting racemic thromboxane receptor antagonist/thromboxane synthase inhibitors is reported, based on the novel approach of linking the known thromboxane synthase inhibitors (TXSI) dazoxiben (2) or isbogrel(11) (separately) to thromboxane receptor antagonists (TXRA) from the 1,3-dioxane series, such as ICI 192605 (10). Dual activity was observed in vitro with inhibition of human microsomal thromboxane synthase in the range IC50 = 0.01-1.0 mu M and receptor antagonist activity by inhibition of U46619-induced human platelet aggregation in the range pA(2) = 5.5-7.0. The in vitro results also showed that very large groups could be tolerated at the selected substitution positions of the TXRA and TXSI components. Oral activity was observed in ex vivo tests in both rats and dogs at a dose of 10 mg/kg. Thus, (E)-7-[4-[[4-[(2SR,4SR,5RS)-5-[(Z)-5-carboxypent-2-enyl]-4-(2-hydroxyphenyl)-1,3-dioxan-2-yl]benzyl]oxy]phenyl]-7-(3-pyridyl)hept-6-enoic acid (110) was both an antagonist (pA(2) = 6.7) and a synthase inhibitor (IC50 = 0.02 mu M). On oral dosing (10 mg/kg) to rats and dogs, 110 showed significant TXRA activity [concentration ratio >64 (rat, 3 h) and >59 +/- 11.3 (dog, 2 h) vs ex vivo U46619-induced platelet aggregation]. Inhibition of thromboxane synthase at the respective time points in these experiments was 81 +/- 4.4% (rat) and 69 +/- 4.8% (dog).

  DOI：

  10.1021/jm00010a005
• 作为产物：
  描述：

  2-(4-(羟基甲基)苯基)乙醇 在 4-(4-fluorophenyl)naphthalene-1,2-dione 、 氧气 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 6.0h， 以76%的产率得到4-(2-羟基乙基)苯甲醛
  参考文献：
  名称：

  仿生邻萘醌催化醇有氧氧化制醛和酮

  摘要：

  在催化量的碱存在下，使用邻萘醌催化剂开发了仿生醇脱氢酶 (ADH) 样氧化方案。开发的有机催化有氧氧化方案通过萘烷氧化物中间体的分子内 1,5-氢原子转移进行，这是与以前的醇脱氢酶模拟物不同的机械特征，该模拟物需要催化剂活性形式的金属。类似 ADH 的有氧氧化方案应该为现有的化学计量和金属催化的醇氧化反应提供绿色替代方案。

  DOI：

  10.1021/acs.orglett.2c02037

文献信息

• Quinolines useful in treating cardiovascular disease
  申请人：Collini D. Michael

  公开号：US20050131014A1

  公开（公告）日：2005-06-16

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了式I化合物的用途，它们在治疗或抑制LXR介导的疾病中是有用的。
• THERAPEUTIC AGENT FOR DIABETES
  申请人：Japan Tobacco Inc.

  公开号：EP0885869A1

  公开（公告）日：1998-12-23

  A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4 and R5 are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6 is a hydrogen atom or an amino-protecting group; R1 is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2 is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3 is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

  用于治疗糖尿病的疗法剂，包括公式[I]的化合物 其中 X是公式的组 其中R4和R5相同或不同，每个都是氢原子，可选地取代的具有1至5个碳原子的烷基等等，R6是氢原子或氨基保护基团；R1是具有1至5个碳原子的可选取代烷基，具有2至6个碳原子的可选取代烯基等等，R2是氢原子，具有1至5个碳原子的可选取代烷基等等，R2'是氢原子，R3是具有1至5个碳原子的可选取代烷基等等，其前药，药用可接受盐，水合物和溶剂化物。 本发明的化合物在血糖升高状态下表现出优越的降血糖作用，但在正常范围或低血糖状态下不影响血糖，这意味着它没有低血糖等严重副作用。因此，本发明的化合物作为治疗糖尿病的药物很有用，也用作预防糖尿病慢性并发症。
• New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040242572A1

  公开（公告）日：2004-12-02

  The present invention relates to carboxamide compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 , R 2 , R 3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及具有通式I的羧酰胺化合物 1 其中，A、B、W、X、Y、Z、R 1 、R 2 、R 3 和k的含义如权利要求1中所述。此外，本发明还涉及制备上述羧酰胺的方法以及含有至少一种根据本发明的羧酰胺的药物组合物。由于它们对MCH受体的拮抗活性，根据本发明的药物组合物适合用于治疗代谢紊乱和/或饮食紊乱，特别是肥胖症、厌食症、暴食症、糖尿病。
• [EN] ETHER COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS D'ÉTHER ET LEURS UTILISATIONS
  申请人：BIOTHERYX INC

  公开号：WO2019040274A1

  公开（公告）日：2019-02-28

  The present invention provides compounds that modulate protein function, to restore protein homeostasis and/or cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions of these compounds are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions are also provided.

  本发明提供了调节蛋白功能的化合物，以恢复蛋白稳态和/或细胞间粘附。该发明提供了调节蛋白介导疾病的方法，如细胞因子介导的疾病、紊乱、状况或反应。还提供了这些化合物的组合物。还提供了治疗、改善或预防蛋白介导的疾病、紊乱和状况的方法。
• Highly Practical Copper(I)/TEMPO Catalyst System for Chemoselective Aerobic Oxidation of Primary Alcohols
  作者：Jessica M. Hoover、Shannon S. Stahl

  DOI：10.1021/ja206230h

  日期：2011.10.26

  Aerobic oxidation reactions have been the focus of considerable attention, but their use in mainstream organic chemistry has been constrained by limitations in their synthetic scope and by practical factors, such as the use of pure O(2) as the oxidant or complex catalyst synthesis. Here, we report a new (bpy)Cu(I)/TEMPO catalyst system that enables efficient and selective aerobic oxidation of a broad

  好氧氧化反应一直是备受关注的焦点，但它们在主流有机化学中的使用受到其合成范围和实际因素的限制，例如使用纯 O(2) 作为氧化剂或复合催化剂合成。在这里，我们报告了一种新的 (bpy)Cu(I)/TEMPO 催化剂系统，该系统能够使用现成的试剂将广泛的伯醇（包括烯丙基、苄基和脂肪族衍生物）高效和选择性地有氧氧化成相应的醛，在室温下，以环境空气为氧化剂。该催化剂体系与多种官能团相容，对 1° 醇的高选择性使缺乏保护基团的二醇能够选择性氧化。